Antibe Therapeutics Inc. (ATE.TO)
- Previous Close
0.2950 - Open
0.2600 - Bid 0.0400 x --
- Ask 0.0400 x --
- Day's Range
0.2600 - 0.3500 - 52 Week Range
0.1500 - 1.2300 - Volume
167,044 - Avg. Volume
131,095 - Market Cap (intraday)
15.638M - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3500 - Earnings Date Feb 13, 2024 - Feb 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.74
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
www.antibethera.comRecent News: ATE.TO
Performance Overview: ATE.TO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATE.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATE.TO
Valuation Measures
Market Cap
15.64M
Enterprise Value
-39.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.60
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
2.15
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.13%
Return on Equity (ttm)
-52.72%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-18.24M
Diluted EPS (ttm)
-0.3500
Balance Sheet and Cash Flow
Total Cash (mrq)
24.91M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.28M
Research Analysis: ATE.TO
Company Insights: ATE.TO
ATE.TO does not have Company Insights